Follow on Google News News By Tag * Rsv * Monoclonal * Antibodies * Market Research Reports * Aggregator * Enterprise And Research * Eor Worldwide Survey * Finance Report * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | MedImmune: collaboration with Trellis strengthens RSV pipelineMedImmune has agreed to license the rights to develop Trellis Bioscience's monoclonal antibody products for the treatment of respiratory syncytial virus (RSV).
By: Bharatbook MedImmune has agreed to license the rights to develop Trellis Bioscience's monoclonal antibody products for the treatment of respiratory syncytial virus (RSV). MedImmune already has one RSV product on the market and has filed for motavizumab, its follow-on compound. However, the efficacy of both products can be improved upon, which may have driven MedImmune's decision to collaborate with Trellis. ( http://www.bharatbook.com/ Trellis Bioscience has granted a worldwide exclusive license to MedImmune, the global biologics unit of AstraZeneca, to develop and commercialize Trellis' antibodies directed against the respiratory syncytial virus (RSV). The RSV antibodies were discovered using Trellis' proprietary CellSpot discovery platform which enables rapid identification and isolation of human antibodies produced from the B-cells of RSV-infected patients. The deal’s value could reach $338 million if a product reaches the market. MedImmune already has one marketed RSV antibody product (Synagis; palivizumab) Recognizing Synagis' shortcomings, MedImmune developed a follow-on compound, motavizumab. This antibody has to-date demonstrated non-inferiority to Synagis but does not offer any significant improvements in terms of efficacy. The company filed for approval of motavizumab in January 2008 but received a Complete Response Letter (CRL) from the FDA asking for additional information. It is yet unclear whether MedImmune has addressed the regulator's questions. In addition to motavizumab, the company is also developing an extended half-life RSV monoclonal antibody, two vaccines for RSV prophylaxis and an F-protein inhibitor for the treatment of RSV infection. MedImmune's collaboration with Trellis comes as a logical step considering the attractive market gap for RSV therapies with improved efficacy. Given that motavizumab does not offer any significant therapeutic benefits over Synagis and the extended release version will only offer improvements in terms of administration, it is likely that MedImmune will develop Trellis' RSV antibodies as successors to motavizumab and may also use them in combination with other RSV products. Other companies with RSV products in development include Pevion Biotech which has an RSV vaccine in preclinical stages, and Cubist Pharmaceuticals which is developing Alnylam's RNAi-based RSV inhibitors. Related research • Monoclonal antibodies: 2009 update http://www.bharatbook.com/ Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: http://twitter.com/ # # # Bharat Book Bureau is the leading business information aggregator providing market research reports and online databases. Bharatbook is also into the business of marketing conferences worldwide and undertakes custom research. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|